For research and educational purposes only. Not medical advice.

Mazdutide Reference

Educational, not medical advice reference for Mazdutide: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule notes…

Reference summary

GLORY-1 (Ji 2025 NEJM, Phase 3, Chinese adults with obesity or overweight, 48 weeks) reported clinically meaningful placebo-subtracted weight reductions at both the 4 mg and 6 mg once-weekly doses, in the range typically reported for GLP-1 / glucagon dual agonists in similar populations. Adverse events were predominantly gastrointestinal (nausea, diarrhea, vomiting), dose-dependent, with most events graded mild to moderate. The trial was conducted in a Chinese population and the Phase 3 program outside of China is at earlier stages.

Regulatory and posture

Categories
GLP-1, Fat Loss
Aliases
IBI362, LY3305677, GLP-1 / glucagon dual receptor agonist
Evidence posture
human - Phase 3 data exist in a Chinese population. Approved in China 2025; investigational outside China.
Regulatory status
Investigational in the United States. Mazdutide is Innovent Biologics' GLP-1 / glucagon dual receptor agonist (originally licensed from Eli Lilly). China's NMPA approved mazdutide in 2025 for adults with obesity or overweight (the first dual-agonist approval in China for this indication). There is no FDA-approved drug label in the US or EU, and mazdutide is not on FDA's approved bulk-substances list for compounding.
Content review status
investigational verified

Selected public sources

Related tools